Document is current
Any future updates will be listed below
-
Authors
Tremblay, Douglas https://orcid.org/0000-0002-4719-7192
Hasserjian, Robert P. https://orcid.org/0000-0002-7753-0697
Rampal, Raajit K.
- License Information
-
More Information
Article History
Received: 1 January 2025
Revised: 8 April 2025
Accepted: 10 April 2025
First Online: 19 April 2025
Competing interests
: DT receives contracted research funding paid to his institution from Sobi, Sumitomo, Cogent Biosciences and Gilead and consulting fees from Sobi, AbbVie, Pharmaessentia, Sierra Oncology, GSK and Cogent Biosciences. RKR receives contracted research funding pain to his institution from Constellation pharmaceuticals, Ryvu, Sumitomo, Zentalis and Stemline Therapeutics and consulting fees from Incyte Corporation, Celgene/BMS, Blueprint, Abbvie, CTI, Stemline, Galecto, Pharmaessentia, Jubilant, Constellation/Morphosys, Sierra Oncology/GSK, Protagonist, Cogent, Sumitomo Dainippon, Kartos, Servier, Zentalis, Karyopharm. RPH declares no relevant conflicts of interest.
